Results 1 - 10 of 71 : 1 2 3 4 5 6 7 8 Next
Coughing Is Bad for Amgen's Health
Safety concerns halt drug trial, but all is not lost.
The drugmaker made a positive move, but seems to be guiding lower.
World's Scariest Stock: Dendreon
A volatile biotech with nowhere to go.
When Science, Marketing, and Investing Collide
How a pharmaceutical tries to sell more drugs can provide clues about its management.
Results IMPACT Volatility at Dendreon
Dendreon almost hits both a 52-week high and a 52-week low on the day it releases results.
The Little Label Expansion That Couldn't
Merck gets Gardasil approved to protect against other cancers.
Fool Poll: Vytorin, Ethics, and the Scientific Process
When health risks are on the line, where does our duty lie?
Uh-oh. Merck's HPV vaccine may not be cost-effective.
Positive earnings, but losses may be ahead.
A Big Upgrade for Onyx Pharmaceuticals
This bullish call comes from more than just one analyst.
Legal Information © 1995 - 2008 The Motley Fool. All rights reserved.
Market Data provided by 
Terms & Conditions
RSS Headlines
Fool UK